Etrumadenant (AB928; AB-928) is a first-in-class, clinical stage, oral and dual antagonist of the A2aR and A2bR adenosine receptors with potential anticancer and immunomodulatory activity. It can prevent adenosine-mediated immunosuppression, thus leading to greater immune activation and reduced tumor growth when combined with chemotherapy.

纯度：≥98%

CAS：2239273-34-6